secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001104659-23-112592
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist Therapeutics expands board to 7, appoints Daniel Swisher as director
--------------------------------------------------------------------------------

- Board increased from 6 to 7 directors; Daniel N. Swisher, Jr. appointed as Class I director effective Oct 26, 2023.
- Swisher most recently President of Jazz Pharmaceuticals (2018-2023); also serves on boards of Cerus and Corcept.
- Receives $40,000 annual cash retainer and option for 45,000 shares at $14.21, vesting over 36 months.
- Standard indemnification agreement entered; term runs until 2026 annual meeting.
- No arrangements or family relationships with other directors or officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923112592/0001104659-23-112592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465923112592/tm2329380d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-112592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer